Axel Hauschild

Researcher Next ID · RN-001999

Researcher · Medicine

Kiel, Germany

Not currently recruitingFunding unknown

Research interests

Medicine

Biochemistry, Genetics and Molecular Biology

Cutaneous Melanoma Detection and Management

Melanoma and MAPK Pathways

Nonmelanoma Skin Cancer Studies

Cancer Immunotherapy and Biomarkers

CAR-T cell therapy research

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1412690
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1406037
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
The Lancet · 2012 · https://doi.org/10.1016/s0140-6736(12)60868-x
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
New England Journal of Medicine · 2011 · https://doi.org/10.1056/nejmoa1103782
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
New England Journal of Medicine · 2011 · https://doi.org/10.1056/nejmoa1104621

No projects listed.